RECRUITING

Individualized Treatments in Adults With Relapsed/Refractory Cancers

Talk to us

Conditions

Refractory CancerRelapsed Cancer

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

A personalized cancer medicine approach would address therapy resistance, cancer metastasis, and limited options after standard of care is exhausted in advanced cancer participants. This approach may reduce the barriers to approved therapeutic assignment currently limited to a particular cancer type or patient demographic.

Official Title

Individualized Treatments in Adults With Relapsed/Refractory Cancers

Quick Facts

Study Start:2023-11-20
Study Completion:2025-11-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06024603

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Participants aged 18 years or older at the time of enrollment on this study of any gender, race, or ethnicity.
  2. * Patients with suspected or confirmed diagnosis of recurrent or refractory cancer with no curative treatment options.
  3. * Participants who have undergone at least two lines of previous therapy.
  4. * Participants who are scheduled for or have recently had biopsy or tumor excised (solid tumors) or bone marrow aspirate (blood cancers) or who have scheduled or recently had paracentesis or thoracentesis performed.
  5. * Participants willing to have a blood draw or buccal swab done for the purposes of genetic testing.
  6. * Participants willing to sign informed consent.
  1. * Participants who do not have malignant tissue available and accessible.
  2. * Participants for whom the amount of excised malignant tissue is not sufficient for the ex vivo drug testing and/or genetic profiling.
  3. * Participants with newly diagnosed tumors and tumors that have high (\>90%) cure rate with safe standard therapy.

Contacts and Locations

Study Contact

Jorge Manrique-Succar, MD
CONTACT
(954) 659-5000
manriqj@ccf.org
Diana Azzam, PhD
CONTACT
305-348-9043
dazzam@fiu.edu

Principal Investigator

Jorge Manrique-Succar, MD
PRINCIPAL_INVESTIGATOR
Lerner College of Medicine, Cleveland Clinic Florida
Diana Azzam, PhD
PRINCIPAL_INVESTIGATOR
Robert Stempel College of Public Health and Social Work, Florida International University

Study Locations (Sites)

Florida International University
Miami, Florida, 33199
United States
Lerner College of Medicine, Cleveland Clinic Florida
Weston, Florida, 33331
United States

Collaborators and Investigators

Sponsor: Case Comprehensive Cancer Center

  • Jorge Manrique-Succar, MD, PRINCIPAL_INVESTIGATOR, Lerner College of Medicine, Cleveland Clinic Florida
  • Diana Azzam, PhD, PRINCIPAL_INVESTIGATOR, Robert Stempel College of Public Health and Social Work, Florida International University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-11-20
Study Completion Date2025-11-01

Study Record Updates

Study Start Date2023-11-20
Study Completion Date2025-11-01

Terms related to this study

Additional Relevant MeSH Terms

  • Refractory Cancer
  • Relapsed Cancer